MDGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MDGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Madrigal Pharmaceuticals's interest income for the three months ended in Jun. 2024 was $14.22 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2024 was $34.81 Mil.
The historical data trend for Madrigal Pharmaceuticals's Interest Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Income | Get a 7-Day Free Trial | 11.02 | 4.33 | 0.36 | 2.19 | 19.58 |
Madrigal Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Interest Income | Get a 7-Day Free Trial | 3.55 | 3.30 | 8.95 | 8.33 | 14.22 |
Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.
Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
William John Sibold | director, officer: President and CEO | C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428 |
Robert E. Waltermire | officer: Senior VP, Chief Pharma Dev. | FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428 |
Fred B Craves | director, 10 percent owner | 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111 |
Paul A Friedman | director, officer: Chief Executive Officer | C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803 |
Rebecca Taub | director, officer: Chief Medical Officer, EVP R&D | 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Kenneth Bate | director | C/O MILLENNIUM PHARMACEUTICALS INC, 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Richard S Levy | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Brian Joseph Lynch | officer: SVP and General Counsel | 480 MORRIS ROAD, BLUE BELL PA 19422 |
Felix Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Raymond Cheong | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
From GuruFocus
By GuruFocus Research • 08-08-2024
By GuruFocus Research • 04-04-2024
By GuruFocus Research • 04-04-2024
By GuruFocus Research • 02-15-2024
By Marketwired • 06-05-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 05-07-2024
By Marketwired • 04-24-2024
By Marketwired • 08-26-2024
By GuruFocus Research • 08-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.